Validation study for assessing COVID-19 pneumonia treatments.

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• COVID-19 pneumonia poses significant clinical challenges.
• Antiviral therapies are crucial for managing severe COVID-19.
• Real-world data is essential for evaluating treatment efficacy.

Purpose of the Study:

• To compare the effectiveness of Azvudine and nirmatrelvir-ritonavir (Paxlovid) in treating COVID-19 pneumonia.
• To identify patient subgroups benefiting from specific antiviral treatments.
• To assess the impact of these antivirals on clinical recovery and disease progression.

Main Methods:

• Retrospective analysis of real-world clinical data from hospitalized COVID-19 patients.
• Utilized kernel density estimation, box-and-whisker plots, and Schoenfeld residual plots.
• Applied Cox regression modeling and developed a nomogram for outcome prediction.

Main Results:

• Both Azvudine and Paxlovid significantly reduced patient recovery times.
• Azvudine demonstrated particular efficacy in patients aged 50-80.
• Improvements in lung CT values and reduced disease severity were observed in moderate cases.

Conclusions:

• Azvudine and Paxlovid are effective in accelerating recovery from COVID-19 pneumonia.
• Personalized treatment strategies, considering age and disease severity, can optimize outcomes.
• Predictive models can aid in clinical decision-making for COVID-19 management.